DT
BCRX icon

Diversified Trust’s BioCryst Pharmaceuticals BCRX Stock Holding History

Diversified Trust’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,795
Closed -$118K – 946
2025
Q1 		$118K Hold
15,795
– – ﹤0.01% 884
2024
Q4 		$119K Sell
15,795
-5,885
-27% -$44.7K ﹤0.01% 877
2024
Q3 		$165K Sell
21,680
-3,072
-12% -$23.4K ﹤0.01% 845
2024
Q2 		$153K Buy
24,752
+3,774
+18% +$20.8K ﹤0.01% 803
2024
Q1 		$107K Hold
20,978
– – ﹤0.01% 790
2023
Q4 		$126K Hold
20,978
– – ﹤0.01% 823
2023
Q3 		$149K Buy
20,978
+2,004
+11% +$14.4K 0.01% 764
2023
Q2 		$134K Hold
18,974
– – ﹤0.01% 785
2023
Q1 		$158K Sell
18,974
-263
-1% -$2.53K 0.01% 768
2022
Q4 		$221K Sell
19,237
-278
-1% -$3.47K 0.01% 701
2022
Q3 		$246K Buy
19,515
+107
+0.6% +$1.38K 0.01% 613
2022
Q2 		$205K Buy
19,408
+1,200
+7% +$12.4K 0.01% 680
2022
Q1 		$296K Hold
18,208
– – 0.01% 623
2021
Q4 		$252K Buy
+18,208
New +$241K 0.01% 694

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Diversified Trust's BCRX Position: Q2 2025 in Review

Diversified Trust sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 15,795 shares — an estimated $118K sold.

Diversified Trust first reported a position in BCRX in Q4 2021 and held it in 14 quarters. The position peaked at $296K in Q1 2022. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

  • Diversified Trust reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Diversified Trust sold 15,795 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $118K.
  • Diversified Trust first reported a position in BioCryst Pharmaceuticals in Q4 2021 and held it in 14 quarters.
  • Diversified Trust's BioCryst Pharmaceuticals position peaked at $296K in Q1 2022.
  • 294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on Diversified Trust's 13F filing for Q2 2025, filed 11 Jul 2025.